News
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...
Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
WFRV Local 5 on MSN6h
New tariffs could raise prices of Ozempic, WegovySome of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...
CNBC's Karen Gilchrist discusses Novo Nordisk's new CEO and the pharma giant's move to cut its full-year guidance on weaker ...
Novo Nordisk's shares have experienced a significant decline due to increasing competition and pressure from the U.S.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback